Flow diagram of patient enrolment, selection, and analysis of SCHOLAR-5 and comparative analysis set. Full eligibility criteria are listed in supplemental Appendix, section 2. Key eligibility criteria for SCHOLAR-5 cohort were: (1) diagnosed r/r FL; (2) starting third or higher line of therapy; (3) on or after 23 July 2014. Prior line of therapy with anti-CD20 monotherapy did not count as line of therapy for eligibility. Key exclusion criteria for the SCHOLAR-5 cohort were (1) transformed FL, (2) FL histological grade 3b, and (3) prior anti-CD19 CAR T-cell therapy or other genetically modified T-cell therapy. Patients were eligible for inclusion in the ZUMA-5 sample if they met the criteria for a minimum follow-up of 18 months.